Loading
A phase 1/2 trial of Rituximab, Cyclophosphamide, Doxorubicin in diffuse large b-cell lymphoma and follicular lymphoma, run by Genmab, active and no longer recruiting.
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) is a phase 1/2 interventional study registered as NCT04663347 by Genmab, with 543 participants enrolled, started 2020-11-03 and due to reach its primary completion in 2027-09-30. Interventions recorded: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, gemcitabine and oxaliplatin. Conditions listed: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Genmab, Prednisone, Vincristine, Rituximab.
Shares Genmab, Lenalidomide, Prednisone, Vincristine.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Lenalidomide, Prednisone, Vincristine, Rituximab.
Shares Genmab, Prednisone, Vincristine, Rituximab.
Shares Lenalidomide, Vincristine, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Vincristine, Rituximab, Follicular lymphoma.
Shares Prednisone, Vincristine, Rituximab, Follicular lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/